Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Portal vein thrombosis pathophysiology

Introduction

Overview

Overview

It seems portal vein thrombosis is caused by Virchow’s triad which includes: Reduced portal blood flow, hypercoagulable state, and vascular endothelial injury. There are two mechanisms that contribute in loss of portal vein blood flow to liver, arterial rescue and venous rescue. It is a rapid process and takes a few days to start and 3-5 weeks to complete after portal vein obstruction. Collateral vessel joins to form cavernoma which connects the proximal and distal part of thrombosed portal vein. Finally, the portal vein becomes a fibrosed and thin cord. All these events leads to low systemic vascular resistance and high. These are the characterstic findings of hyperkinetic circulation.

Structure

Structure

Tributaries

The tributaries of the hepatic portal vein include:

Pathophysiology

Pathophysiology

Pathogenesis

<figure-inline><figure-inline><figure-inline><figure-inline></figure-inline></figure-inline></figure-inline></figure-inline>

Shown below is a table depicting the elements of Virchow’s triad and their modern counterparts.

Virchow’s[2] Modern Notes
Phenomena of interrupted blood-flow “Stasis” or “venous stasis“[3]
Phenomena associated with irritation of the vessel and its vicinity “Endothelial injury” or “vessel wall injury”
Phenomena of blood–coagulation “Hypercoagulability”
Genetics

Genetics

  • The development of portal vein thrombosis is the result of G201210A mutations.
Associated Conditions

Associated Conditions

Gross Pathology

Gross Pathology

Microscopic Pathology

Microscopic Pathology

  • There is no finding on microscopic histopathological analysis.
References

References

  1. ↑ 1.0 1.1 Chawla YK, Bodh V (2015). “Portal vein thrombosis”. J Clin Exp Hepatol. 5 (1): 22–40. doi:10.1016/j.jceh.2014.12.008. PMCΒ 4415192. PMIDΒ 25941431.
  2. ↑ Agutter, Paul S. (2008). The Aetiology of Deep Venous Thrombosis: A Critical, Historical and Epistemological Survey. Berlin: Springer. p.Β 84. ISBNΒ 1-4020-6649-X.
  3. ↑ Lowe GD (2003). “Virchow’s triad revisited: abnormal flow”. Pathophysiol. Haemost. Thromb. 33 (5–6): 455–7. doi:10.1159/000083845. PMIDΒ 15692260.
  4. ↑ “Further reflections on Virchow’s triad. – Free Online Library”. Retrieved 2009-02-10.
  5. ↑ Chung I, Lip GY (2003). “Virchow’s triad revisited: blood constituents”. Pathophysiol. Haemost. Thromb. 33 (5–6): 449–54. doi:10.1159/000083844. PMIDΒ 15692259.
  6. ↑ Zhang WW, Churchill S, Churchill P (1989). “Developmental regulation of D-beta-hydroxybutyrate dehydrogenase in rat liver and brain”. FEBS Lett. 256 (1–2): 71–4. PMIDΒ 2806552.
  7. ↑ Henderson JM, Gilmore GT, Mackay GJ, Galloway JR, Dodson TF, Kutner MH (1992). “Hemodynamics during liver transplantation: the interactions between cardiac output and portal venous and hepatic arterial flows”. Hepatology. 16 (3): 715–8. PMIDΒ 1505914.
  8. ↑ De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K (1995). “Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography”. AJR Am J Roentgenol. 165 (5): 1151–5. doi:10.2214/ajr.165.5.7572494. PMIDΒ 7572494.
  9. ↑ Hoekstra J, Janssen HL (2009). “Vascular liver disorders (II): portal vein thrombosis”. Neth J Med. 67 (2): 46–53. PMIDΒ 19299846.
  10. ↑ Wang JT, Zhao HY, Liu YL (2005). “Portal vein thrombosis”. HBPD INT. 4 (4): 515–8. PMIDΒ 16286254.
  11. ↑ Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, Hadengue A, Erlinger S, Valla D (2001). “Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy”. Gastroenterology. 120 (2): 490–7. PMIDΒ 11159889.
  12. ↑ Garcia-PagΓ‘n JC, HernΓ‘ndez-Guerra M, Bosch J (2008). “Extrahepatic portal vein thrombosis”. Semin. Liver Dis. 28 (3): 282–92. doi:10.1055/s-0028-1085096. PMIDΒ 18814081.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]